Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
- PMID: 35874458
- PMCID: PMC9297041
- DOI: 10.2147/CCID.S289750
Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
Abstract
The purpose of this narrative review is to provide a summary of the clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) to grant providers an understanding of which patients will benefit most from this novel topical antiandrogen medication. Clascoterone 1% cream (Winlevi) offers a new and exciting treatment approach for a difficult and common skin condition such as acne vulgaris. This topical androgen antagonist is the first of its kind but will hopefully provoke investigations into other androgen receptor antagonists with similar or better efficacy.
Keywords: CB-03-01; Winlevi; anti-androgens; hormonal acne.
© 2022 Sanchez and Keri.
Conflict of interest statement
Dr Jonette Keri reports being a consultant for Almirall, being on the advisory board for Ortho dermatologics, research study from Galderma, during the conduct of the study. The authors report no other conflicts of interest in this work.
Figures

Similar articles
-
Individual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne.J Drugs Dermatol. 2023 Jun 1;22(6):SF350992s7-SF350992s14. J Drugs Dermatol. 2023. PMID: 37276168
-
Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years.Clin Ther. 2021 Oct;43(10):1638-1644. doi: 10.1016/j.clinthera.2021.08.007. Epub 2021 Oct 2. Clin Ther. 2021. PMID: 34607697 Review.
-
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. JAMA Dermatol. 2020. PMID: 32320027 Free PMC article. Clinical Trial.
-
Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne.Ann Pharmacother. 2021 Oct;55(10):1290-1296. doi: 10.1177/1060028021992053. Epub 2021 Feb 3. Ann Pharmacother. 2021. PMID: 33533262 Review.
-
Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study.J Drugs Dermatol. 2019 Jun 1;18(6):563. J Drugs Dermatol. 2019. PMID: 31251549 Clinical Trial.
Cited by
-
Acne vulgaris: advances in pathogenesis and prevention strategies.Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):515-532. doi: 10.1007/s10096-024-04984-8. Epub 2025 Jan 15. Eur J Clin Microbiol Infect Dis. 2025. PMID: 39815129 Review.
References
-
- Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412–418. - PubMed
Publication types
LinkOut - more resources
Full Text Sources